ライフサイエンスコーパス: interferon alfa-2a

1 patients receiving combination treatment or interferon alfa-2a.

2 compared peginterferon alfa-2a (40 kd) with interferon alfa-2a.

3 1 IU/mL before the introduction of pegylated interferon alfa-2a.

4 sed double-blind placebo-controlled trial of interferon alfa-2a (10 million units/m2, daily for 7 day

5 Use of interferon alfa-2a/2b and ribavirin, 1000 to 1200 mg/d,

6 trial involving 674 patients, the effect of interferon alfa-2a (3 megaunits three times per week for

7 day), peginterferon alfa-2a plus placebo, or interferon alfa-2a (3 million IU three times a week) plu

8 days, then 750 mg/m2 weekly, and recombinant interferon alfa-2a 9 million units subcutaneously three

9 r 90 mug/week (for arm B) of pegylated (Peg) interferon alfa-2a added to their current ART regimen.

10 Pegylated interferon alfa-2a administered once weekly is more effe

11 once weekly is more effective than standard interferon alfa-2a administered three times weekly.

12 ined virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepati

13 llocated (1 to 1) by minimisation to receive interferon alfa-2a alone or combination therapy with int

14 l or progression-free survival compared with interferon alfa-2a alone, immunotherapy might still have

15 ere reported in 113 (23%) patients receiving interferon alfa-2a and 131 (26%) of those receiving comb

16 2 patients were randomly assigned to receive interferon alfa-2a and 504 to receive combined treatment

17 , >17 000 IU/mL) were treated with pegylated interferon alfa-2a and adefovir for 48 weeks.

18 Therapy for HCL includes splenectomy, interferon alfa-2a and alfa-2b, pentostatin, and cladrib

19 jection (CR) in patients receiving pegylated interferon alfa-2a and ribavirin (PEG) to treat recurren

20 8), telaprevir in combination with pegylated interferon alfa-2a and ribavirin (Peg-IFN/RBV) for 15 da

21 zed 1:1:2:2 to receive 24 weeks of pegylated interferon alfa-2a and ribavirin (PegIFN/RBV) in combina

22 th TMC435 (200 mg once daily) plus pegylated interferon alfa-2a and ribavirin (PegIFNalpha-2a and RBV

23 (Virahep-C), 260 men treated with pegylated interferon alfa-2a and ribavirin completed self-administ

24 All patients received pegylated interferon alfa-2a and ribavirin therapy.

25 ng recombinant interleukin-2 and recombinant interferon alfa-2a before and after combination cytotoxi

26 d) provides improved sustained response over interferon alfa-2a, but its effect on HRQL is unknown.

27 INTERPRETATION: Pegylated interferon alfa-2a can induce durable haematological and

28 The doses of interferon alfa-2a given in this regimen did not improve

29 t a dose of 200 mg plus 180 mug of pegylated interferon alfa-2a (group 4), or a nucleoside or nucleot

30 owledge, the antiviral activity of pegylated interferon alfa-2a has not been studied in participants

31 A variety of regimens of interferon alfa-2a have been used, including use of high

32 e maximum-tolerated dosage (MTD) of IL-2 and interferon alfa-2a (IFN alpha-2a) that can be administer

33 Interferon alfa-2a (IFN-alpha2a) was administered at 9 m

34 etyl-L-aspartic acid (PALA), and recombinant interferon alfa-2a (IFNalpha-2a) in a sequential order t

35 Pegylated (40 kd) interferon alfa-2a (IFNalpha2a) (PEGASYS, Hoffman-La Roc

36 rapy with 13-cis-retinoic acid (13-CRA) plus interferon alfa-2a (IFNalpha2a) is superior to IFNalpha2

37 Peg-interferon alfa-2a immunotherapy resulted in control of

38 34 partial responders treated with pegylated interferon alfa-2a in MPN-112; and eight (27%) of 30 com

39 35 partial responders treated with pegylated interferon alfa-2a in MPN-RC 111; five (19%) of 27 compl

40 linical-haematological response to pegylated interferon alfa-2a in patients who were resistant or int

41 afety and efficacy of REP 2139 and pegylated interferon alfa-2a in patients with chronic HBV and hepa

42 Pegylated interferon alfa-2a induced haematological (66 [80%] of 8

43 astatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil prod

44 on alfa-2a alone or combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil.

45 Pegylated interferon alfa-2a is an immunomodulatory agent used to

46 The side effect profile of interferon alfa-2a is similar to that of other interfero

47 form of ropeginterferon alfa-2b or pegylated interferon alfa-2a, is the recommended cytoreductive tre

48 om burden, both those treated with pegylated interferon alfa-2a (mean total symptom score change -10.

49 ptom burden (patients treated with pegylated interferon alfa-2a: mean total symptom score change 3.2,

50 At week 12 of Peg-interferon alfa-2a monotherapy, viral suppression was ob

51 REP 2139 and 180 mug subcutaneous pegylated interferon alfa-2a once per week for 15 weeks, then mono

52 eks, then monotherapy with 180 mug pegylated interferon alfa-2a once per week for 33 weeks.

53 Seven were treated with corticosteroids, interferon alfa-2a, or both.

54 patitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV)

55 We conducted a phase II study of pegylated interferon alfa-2a (PEG-IFN-alpha-2a) in patients with e

56 of sofosbuvir (SOF), ribavirin (RBV) and peg-interferon-alfa-2a (peg-IFN-alfa-2a) as well as the comb

57 -label subcutaneous treatment with pegylated interferon-alfa-2a (Peg-IFNalfa-2a) 180 mug/wk, or albIF

58 ovir disoproxil fumarate (TDF) and pegylated interferon alfa-2a (pegIFN) in patients with chronic HBV

59 ompared the efficacy and safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either r

60 of sofosbuvir in combination with pegylated interferon alfa-2a (peginterferon) and ribavirin in non-

61 plus ribavirin than among those assigned to interferon alfa-2a plus ribavirin (40 percent vs. 12 per

62 a lower likelihood of SVR than was pegylated interferon alfa-2a plus ribavirin (absolute difference,

63 us either ribavirin or placebo with those of interferon alfa-2a plus ribavirin for the treatment of c

64 was significantly more effective than either interferon alfa-2a plus ribavirin or peginterferon alfa-

65 ron alfa-2a plus placebo, and 7 percent with interferon alfa-2a plus ribavirin.

66 Interferon alfa-2a resembles other recombinant alpha int

67 imeprevir (150 mg once daily) with pegylated interferon alfa-2a/ribavirin (peg-IFN/RBV) for 12 weeks.

68 4 weeks' therapy with four weekly PEGylated interferon alfa-2a subcutaneous injections; induction an

69 ERPRETATION: Combined REP 2139 and pegylated interferon alfa-2a therapy is safe, well tolerated, and

70 cts were assigned to receive 6 million IU of interferon alfa-2a three times weekly for 12 weeks follo

71 .8 months (17.0-23.2) for patients receiving interferon alfa-2a versus 18.6 months (16.5-20.6) for th

72 linical-haematological response to pegylated interferon alfa-2a versus hydroxyurea in therapy-naive p

73 The initial starting dose of pegylated interferon alfa-2a was 450 mug subcutaneously once per w

74 After 5 weeks, ART was interrupted, and Peg-interferon alfa-2a was continued for up to 12 weeks (the

75 uvant chemoprevention with retinoic acid and interferon alfa-2A was offered.

76 Pegylated interferon alfa-2a was well tolerated and exhibited stat

77 V infection received 180 microg of pegylated interferon alfa-2a weekly for 12 weeks.